Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Aeterna Zentaris stock

Learn how to easily invest in Aeterna Zentaris stock.

Aeterna Zentaris is a biotechnology business based in the US. Aeterna Zentaris shares (AEZS) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy Aeterna Zentaris stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – AEZS. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award

eToro


  • Trade stocks and ETFs for $0 and no annual fee
  • Minimum deposit of $10 required
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience

Robinhood


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Aeterna Zentaris stock price (NASDAQ: AEZS)

Use our graph to track the performance of AEZS stocks over time.

Aeterna Zentaris shares at a glance

Information last updated 2023-02-02.
Latest market close$3.76
52-week range$2.89 - $10.99
50-day moving average $3.60
200-day moving average $4.61
Wall St. target price$28.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.08

Buy Aeterna Zentaris stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
eToro
Stocks, Options, ETFs, Cryptocurrency
$0
$10
FINDER EXCLUSIVE: Get $15
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Aeterna Zentaris stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aeterna Zentaris price performance over time

Historical closes compared with the close of $3.76 from 2023-02-01

1 week (2023-01-27) 0.80%
1 month (2023-01-03) 16.77%
3 months (2022-11-03) -3.59%
6 months (2022-08-03) -25.10%
1 year (2022-01-30) N/A
2 years (2021-02-03) 295.79%
3 years (2020-02-03) 261.54%
5 years (2018-02-02) 79.90%

Aeterna Zentaris financials

Revenue TTM $4.1 million
Gross profit TTM $5.2 million
Return on assets TTM -12.09%
Return on equity TTM -24.09%
Profit margin 0%
Book value $10.18
Market capitalisation $18.3 million

TTM: trailing 12 months

Aeterna Zentaris share dividends

We're not expecting Aeterna Zentaris to pay a dividend over the next 12 months.

Have Aeterna Zentaris's shares ever split?

Aeterna Zentaris's shares were split on a 1:25 basis on 20 July 2022. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aeterna Zentaris shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Aeterna Zentaris shares which in turn could have impacted Aeterna Zentaris's share price.

Aeterna Zentaris share price volatility

Over the last 12 months, Aeterna Zentaris's shares have ranged in value from as little as $2.89 up to $10.9875. A popular way to gauge a stock's volatility is its "beta".

AEZS.US volatility(beta: 1.66)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeterna Zentaris's is 1.6637. This would suggest that Aeterna Zentaris's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Aeterna Zentaris overview

Aeterna Zentaris Inc. , a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd.

Frequently asked questions

What percentage of Aeterna Zentaris is owned by insiders or institutions?
Currently 0.337% of Aeterna Zentaris shares are held by insiders and 0.599% by institutions.
When does the fiscal year end for Aeterna Zentaris?
Aeterna Zentaris's fiscal year ends in December.
Where is Aeterna Zentaris based?
Aeterna Zentaris's address is: 315 Sigma Drive, Summerville, SC, United States, 29486
What is Aeterna Zentaris's ISIN number?
Aeterna Zentaris's international securities identification number is: CA0079754028
What is Aeterna Zentaris's CUSIP number?
Aeterna Zentaris's Committee on Uniform Securities Identification Procedures number is: 007975105

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site